Compare ARDX & ARCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | ARCB |
|---|---|---|
| Founded | 2007 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trucking Freight/Courier Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2014 | N/A |
| Metric | ARDX | ARCB |
|---|---|---|
| Price | $5.80 | $69.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | $10.65 | ★ $90.91 |
| AVG Volume (30 Days) | ★ 2.7M | 333.9K |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 0.69% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.20 |
| Revenue | $398,234,000.00 | ★ $4,039,115,000.00 |
| Revenue This Year | $22.71 | N/A |
| Revenue Next Year | $27.81 | $3.87 |
| P/E Ratio | ★ N/A | $16.56 |
| Revenue Growth | ★ 58.12 | N/A |
| 52 Week Low | $3.21 | $55.19 |
| 52 Week High | $6.78 | $113.74 |
| Indicator | ARDX | ARCB |
|---|---|---|
| Relative Strength Index (RSI) | 53.23 | 56.47 |
| Support Level | $5.73 | $61.56 |
| Resistance Level | $6.20 | $73.32 |
| Average True Range (ATR) | 0.29 | 2.73 |
| MACD | 0.01 | 1.07 |
| Stochastic Oscillator | 57.78 | 73.22 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.